| abstract |
Embodiments of the present disclosure provide for γ-AApeptides, γ-AApeptide building blocks, methods of making γ-AApeptides and libraries of γ-AApeptides, methods of screening the γ-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for γ-AApeptides that are inhibitors of Αβ peptide aggregation, methods of inhibiting and disassembling Αβ peptide aggregation, methods of inhibiting the toxicity of Αβ aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease. |